These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30007073)

  • 1. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria.
    Santiago L; Ferreira B; Ramos L; Gonçalo M
    Br J Dermatol; 2019 Jan; 180(1):199-200. PubMed ID: 30007073
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
    Koski R; Kennedy KK
    Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
    [No Abstract]   [Full Text] [Related]  

  • 3. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change.
    Ertas R; Ozyurt K; Atasoy M; Hawro T; Maurer M
    Allergy; 2018 Mar; 73(3):705-712. PubMed ID: 29083482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
    Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
    Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma D-dimer levels and clinical response to ciclosporin in severe chronic spontaneous urticaria.
    Asero R
    J Allergy Clin Immunol; 2015 May; 135(5):1401-3. PubMed ID: 25542882
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of biomarkers for predicting the response to cyclosporine A therapy in patients with chronic spontaneous urticaria.
    Endo T; Toyoshima S; Kanegae K; Izaki S; Nishimori N; Ito M; Sugai K; Hayama K; Terui T; Okayama Y
    Allergol Int; 2019 Apr; 68(2):270-273. PubMed ID: 30355455
    [No Abstract]   [Full Text] [Related]  

  • 7. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
    Metz M; Ohanyan T; Church MK; Maurer M
    J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.
    Marzano AV; Genovese G; Casazza G; Fierro MT; Dapavo P; Crimi N; Ferrucci S; Pepe P; Liberati S; Pigatto PD; Offidani A; Martina E; Girolomoni G; Rovaris M; Foti C; Stingeni L; Cristaudo A; Canonica GW; Nettis E; Asero R
    J Eur Acad Dermatol Venereol; 2019 May; 33(5):918-924. PubMed ID: 30451325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic urticaria with high IgE levels: first results on oral cyclosporine A treatment.
    Guaragna MA; Albanesi M; Stefani S; Franconi G; Di Stanislao C; Paparo Barbaro S
    Clin Ter; 2013; 164(2):115-8. PubMed ID: 23698203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria.
    Ertas R; Ozyurt K; Ozlu E; Ulas Y; Avci A; Atasoy M; Hawro T; Maurer M
    J Allergy Clin Immunol; 2017 Dec; 140(6):1749-1751. PubMed ID: 28870460
    [No Abstract]   [Full Text] [Related]  

  • 11. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria.
    Cugno M; Asero R; Ferrucci S; Lorini M; Carbonelli V; Tedeschi A; Marzano AV
    Allergy; 2018 Dec; 73(12):2408-2411. PubMed ID: 30076634
    [No Abstract]   [Full Text] [Related]  

  • 12. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
    Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
    J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab also successful in chronic urticaria.
    Spector SL; Tan RA
    J Allergy Clin Immunol; 2008 Mar; 121(3):784; author reply 784-5. PubMed ID: 18328900
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
    Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
    J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
    [No Abstract]   [Full Text] [Related]  

  • 16. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
    Weller K; Ohanyan T; Hawro T; Ellrich A; Sussman G; Koplowitz J; Gimenez-Arnau AM; Peveling-Oberhag A; Staubach P; Metz M; Maurer M
    Allergy; 2018 Dec; 73(12):2406-2408. PubMed ID: 30076605
    [No Abstract]   [Full Text] [Related]  

  • 17. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
    Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
    Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
    Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
    Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current challenges and controversies in the management of chronic spontaneous urticaria.
    Asero R; Pinter E; Marra AM; Tedeschi A; Cugno M; Marzano AV
    Expert Rev Clin Immunol; 2015; 11(10):1073-82. PubMed ID: 26174347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.